Glucagon for Hypoglycemia: A Technical Pros and Cons Analysis
Published: July 15, 2026 03:02
Author: Julia Clayton
Abstract: Glucagon for hypoglycemia, a critical peptide therapeutic, demonstrates rapid efficacy but faces stability and formulation challenges. Market trends show a shift toward ready-to-use auto-injectors (e.g., Baqsimi, Glucagon Emergency Kit). Technical pros include fast glucose elevation; cons involve short shelf-life and nausea. Brand comparison highlights Novo Nordisk’s dominance in nasal vs. injectable formats. Product parameters (e.g., 1 mg dose, 1 mg/mL concentration) vary by device. Industry data projects 8.5% CAGR (2023-2030), driven by diabetes prevalence. Sourcing requires GMP-certified factories and cold-chain logistics.